Scholar Rock has crossed from a delayed biologics applicant into a commercial company. The Food and Drug Administration approved ISEMBYLD, the firm's myostatin-blocking antibody, in mid-September for children and adults with spinal muscular atrophy who already take an SMN-directed medicine. That label is broad across disease types and walking status, and it arrives after a year lost to a third-party fill-finish Complete Response Letter. The equity debate is no longer whether the antibody works. It is whether a first-time seller can turn an add-on rare-disease product into paid demand before the cash runway and the European reset become the story.
The second-quarter print still showed no product sales, which is the right way to read a company that only just received a license. Cash, cash equivalents, and marketable securities stood at $492 million at mid-year. That pile reflects both an at-the-market equity program and a Blue Owl term loan that already funded $200 million. General and administrative spending has already been rebuilt around a field force, so the cost of being commercial is in the run-rate before the first invoice. The counterargument is simple: add-on pricing on top of Biogen and Roche SMN products invites payer friction, and the label carries an unexpected fracture caution that was not the center of the late-stage conversation.
What the next several quarters resolve is conversion, not chemistry. Watch paid starts and formulary decisions in the United States, the timing of a European resubmission after the firm withdrew the prior application when Catalent Indiana received an Official Action Indicated classification, and whether the remaining delayed-draw under Blue Owl stays unused because product cash arrives. A clean launch would justify treating the equity as a rare-disease franchise. A stalled one would re-open the dilution debate the at-the-market program already previewed.